AUG 10, 2026 · PHASE 1/2 TRIAL
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
ClinicalTrials.gov
This is a first-in-human, phase 1/2 trial registration with no results posted; the study is actively recruiting and designed to establish safety, tolerability, and initial antitumor activity of a novel pan-KRAS inhibitor.
Reported
Planned sample size265
Study phasePhase 1/2
Primary outcome: Dose-limiting to…Percentage of participants, up to 5 years